Anesiva Announces Pivotal Phase 3 Clinical Trial Of Adlea(TM) For Reducing Post-Surgical Pain Following Total Knee Replacement
Anesiva, Inc. (Nasdaq: ANSV) announced that a pivotal Phase 3 clinical trial evaluating Adlea(TM), its long-acting, non-opioid analgesic drug candidate, in patients following total knee replacement surgery, is underway.
More: continued here
Filed under: Bones on April 11th, 2008